Acumapimod, an oral p38 inhibitor currently undergoing clinical trials in severe acute COPD exacerbations, showed an improvement in lung function (forced expiratory volume in 1 s; FEV1) when compared to a placebo [180]. The gene discussed is MAPK14; the disease is chronic obstructive pulmonary disease.